CLOS
FATE icon

Compagnie Lombard Odier SCmA’s Fate Therapeutics FATE Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,800
Closed -$45K – 651
2022
Q2 		$45K Hold
1,800
– – ﹤0.01% 453
2022
Q1 		$70K Buy
+1,800
New +$69.7K ﹤0.01% 414

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Compagnie Lombard Odier SCmA's FATE Position: Q3 2022 in Review

Compagnie Lombard Odier SCmA sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 1,800 shares — an estimated $45K sold.

Compagnie Lombard Odier SCmA first reported a position in FATE in Q1 2022 and held it in 2 quarters. The position peaked at $70K in Q1 2022. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Compagnie Lombard Odier SCmA reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1,800 Fate Therapeutics shares in Q3 2022, an estimated $45K.
  • Compagnie Lombard Odier SCmA first reported a position in Fate Therapeutics in Q1 2022 and held it in 2 quarters.
  • Compagnie Lombard Odier SCmA's Fate Therapeutics position peaked at $70K in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2022, filed 9 Nov 2022.